PAX8 and thyroid cancer: Almost all of the 1714 (99.9%) tumors with PAX8/CDH16 dual positivity were derived from kidney/female genital tract/thyroid. Of note, CDH16 is not a recommendable marker for thyroid cancer detection, because it is often lost in thyroidal carcinomas.